Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.
Status:
Recruiting
Trial end date:
2024-04-28
Target enrollment:
Participant gender:
Summary
It is a phase II trial, randomized, parallel, double blind, multicenter, comparing riluzole
versus placebo.
The trial population is composed of patients ≥18 years old that have developed stage II/III
colorectal cancer and are eligible for Simplified FOLFOX4 (6-12 cycles) adjuvant
chemotherapy.
The primary objective is to assess the preventive efficacy of riluzole on the severity of
oxaliplatin-induced peripheral neuropathy during the Simplified FOLFOX4 adjuvant chemotherapy
of stage II/III colorectal cancers.